In this issue:
GEMINI 1 & 2: tolebrutinib vs. teriflunomide in relapsing MS
HERCULES: tolebrutinib in non-relapsing SPMS
Three distinct endophenotypes of MS
Broad rim lesions as a biomarker for rapid disease progression in MS
PIRA as an outcome measure in RRMS clinical trials
Coffee intake & MS risk
LymphoTEC: real-world lymphocyte reconstitution after lymphopaenia with dimethyl fumarate in RRMS
MS diagnosis based on extensive DIS alone
Repeated COVID-19 vaccination in patients with MS receiving ocrelizumab
Complement activation profiles reflect structural brain damage in MS
Please login below to download this issue (PDF)